Welcome to our dedicated page for Alphatec Hldgs SEC filings (Ticker: ATEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused medical device company. ATEC uses current reports on Form 8-K to furnish press releases on topics such as quarterly financial results, material corporate events, and board matters. For example, recent 8-K filings reference press releases announcing financial results for periods ended June 30 and September 30, 2025, as well as a release regarding the passing of a member of the Board of Directors.
In addition to 8-Ks, investors typically review ATEC’s annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of its spine surgery business, revenue composition (including surgical and EOS revenue), non-GAAP metrics such as adjusted EBITDA and free cash flow, and risk factors. These periodic reports also describe the company’s Organic Innovation Machine™, InformatiX™ and AlphaInformatiX platforms, and its focus on procedural spine ecosystems.
Regulatory filings can also reflect strategic and capital structure developments, such as refinancings of convertible debt, transaction-related expenses, and non-GAAP adjustments for items like litigation-related expenses, stock-based compensation, and restructuring costs. Forms 3, 4, and 5, when filed, provide insight into insider equity transactions by directors, officers, and significant shareholders.
On Stock Titan, ATEC’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as revenue trends, segment performance, non-GAAP reconciliations, and notable risk disclosures. For complex filings like 10-Ks and 10-Qs, the AI tools surface essential information so users can quickly understand how Alphatec’s spine-focused strategy, financial profile, and regulatory disclosures are evolving without reading every page.
Craig Hunsaker reported insider sales. The filing shows 66,041 RSUs and 162,665 PSUs were sold to cover with trade dates listed as 03/05/2026 and an execution/settlement date of 03/06/2026. It also lists a prior sale of 32,584 common shares on 12/10/2025. The broker is shown as Merrill Lynch.
Issuer submitted a Form 144 notice reporting proposed sales of equity-linked awards by an affiliated holder. The filing lists 31,916 Restricted Stock Units and 56,919 Performance Stock Units, each dated 03/05/2026.
The filing is a routine Rule 144 notice of intended sale under resale restrictions and does not by itself consummate transactions.
Alphatec Holdings, Inc. announced that longtime director Ward W. Woods chose to retire from its Board of Directors, effective February 27, 2026, for personal reasons. The company states his departure is not due to any disagreement regarding its operations, policies, or practices.
Mr. Woods, who also served on the Board’s Compensation Committee, entered into a Vesting Acceleration Agreement with Alphatec. Under this agreement, any restricted stock units granted to him on June 11, 2025 that remain unvested on his departure date will become fully vested. Following his resignation, the Board reduced its size from eight to seven directors to match the new composition.
Marshall Tyson Eliot reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings reported that its General Counsel and Corporate Secretary, Marshall Tyson Eliot, received multiple equity awards on February 25, 2026. He was granted 205,094 restricted stock units (RSUs) tied to a prior performance-based award for the fiscal year ended December 31, 2025, vesting in three annual installments starting March 5, 2026.
He also received 84,918 RSUs vesting annually from March 5, 2027 through March 5, 2029, and 12,840 RSUs granted in lieu of a portion of his 2025 cash bonus, vesting on December 4, 2026. In addition, he was granted an award of up to 42,459 performance-based RSUs that vest only if specified stock price or operational metrics are achieved by dates running through December 31, 2030. Related common stock awards increased his directly held common shares to 648,294 at no cash cost to him.
Sponsel David reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings EVP of Sales David Sponsel reported multiple equity awards from the company. On February 25, 2026, he was awarded 205,094 restricted stock units (RSUs) tied to a prior performance-based award for the fiscal year ended December 31, 2025, vesting in three equal installments on March 5 of 2026, 2027, and 2028.
He also received 93,410 RSUs vesting in three equal installments on March 5 of 2027, 2028, and 2029, plus 20,380 RSUs granted in lieu of a portion of his 2025 cash bonus that vest on December 4, 2026. In addition, Sponsel was granted up to 46,705 performance-based RSUs that vest only if Alphatec’s common stock reaches 30‑day average prices of at least $25.00 or $36.00 per share by specified dates, or if certain operational metrics determined by the compensation committee are achieved.
Koning John Todd reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings, Inc. chief financial officer John Todd Koning reported multiple equity awards dated February 25, 2026. He was credited with 205,094 restricted stock units tied to a performance-based award for the fiscal year ended December 31, 2025, vesting in three equal installments on March 5, 2026, March 5, 2027, and March 5, 2028.
He also received 110,394 additional RSUs vesting in three equal installments on March 5, 2027, March 5, 2028, and March 5, 2029, and 20,380 RSUs granted instead of a portion of his 2025 cash bonus, vesting on December 4, 2026. The filing notes forfeiture of 32,403 previously reported RSUs for not meeting performance criteria and awards of up to 55,197 performance-based RSUs that vest only if specified stock price and operational metrics are achieved by dates through December 31, 2030.
Lish Scott reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings, Inc. chief operating officer Scott Lish reported several equity awards on February 25, 2026. He received 311,110 restricted stock units tied to previously set 2025 performance goals, 127,378 time-based RSUs, and 20,992 RSUs granted in lieu of part of his 2025 cash bonus. He also received performance-based RSU awards of up to 63,689 units that vest only if Alphatec’s stock reaches 30-day average prices of $25 or $36 per share or specific operational targets are achieved by dates through 2030. These are stock grants, not open-market share purchases or sales.
Hunsaker Craig E reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings EVP Craig E. Hunsaker reported multiple equity grants from the company. On February 25, 2026, he was awarded 311,110 restricted stock units tied to a prior performance-based award, vesting in three equal installments on March 5 of 2026, 2027, and 2028.
He also received 127,378 RSUs vesting in three installments on March 5 of 2027, 2028, and 2029, plus 20,992 RSUs granted in lieu of part of his 2025 cash bonus that vest on December 4, 2026.
In addition, Hunsaker was granted performance-based awards of up to 63,689 RSUs, which vest only if Alphatec’s stock reaches 30‑day average prices of $25.00 or $36.00 by specified dates, or if certain operational metrics are met as of December 31, 2028 or December 31, 2030.
Miles Patrick reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings CEO Patrick Miles reported multiple equity awards dated February 25, 2026. He received 611,673 restricted stock units (RSUs) tied to a performance-based award originally granted January 29, 2025, after confirmation that performance goals for the year ended December 31, 2025 were met. These RSUs vest in three equal installments on March 5 of 2026, 2027, and 2028.
He was also granted 305,707 additional RSUs vesting in three equal installments on March 5 of 2027, 2028, and 2029, and 48,913 RSUs in lieu of part of his 2025 cash bonus that vest on December 4, 2026. Separately, he was awarded two performance-based RSU tranches of up to 152,853 units each, which vest only if Alphatec’s stock achieves 30-day average prices of $25.00 or $36.00 per share by specified dates or if certain operational metrics set by the compensation committee are achieved by December 31, 2028 or 2030.
Alphatec Holdings (ATEC) is a spine-focused medical technology company aiming to “be the standard bearer in spine” through clinically distinct, procedure-based solutions. It designs and sells integrated platforms spanning implants, biologics, neuromonitoring, imaging, planning software and emerging navigation/robotics to improve predictability and reproducibility in spine surgery.
For the year ended December 31, 2025, Alphatec generated $764.2 million in total revenue, up $152.6 million, or 25%, from $611.6 million in 2024, driven by broader adoption of approach-specific procedures such as PTP, LTP and deformity offerings. Surgical volume grew 22% and average revenue per surgery increased 4% versus 2024, reflecting deeper surgeon usage as its portfolio expands.
The company’s strategy centers on three pillars: creating clinical distinction through continuous innovation (including the InformatiX platform with EOS imaging and EOS Insight software, SafeOp neuromonitoring and Valence navigation/robotics), compelling surgeon adoption via its ATEC Experience training programs, and elevating distribution by building an exclusive, clinically sophisticated sales network in the U.S. and targeted international markets.